Pfizer Beats Q1 2026 Estimates on Strong Oncology Performance
Pfizer reported Q1 2026 revenue of $14.45 billion and net income of $2.69 billion, with EPS slightly down year-over-year. The company reaffirmed full-year 2026 revenue guidance of $59.5B–$62.5B and advanced its oncology pipeline with positive Phase 3 data for ELREXFIO and a first FDA approval.
Key Numbers
Pfizer Inc. (NYSE: PFE) reported first-quarter 2026 results, with revenue of $14.45 billion and net income of $2.69 billion, beating analyst estimates. Despite a slight year-over-year decline in earnings per share, the company reaffirmed its full-year revenue guidance.
Key Financial Results
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Revenue | $14.45B | - |
| Net Income | $2.69B | - |
| EPS | $0.48 | Slight decline |
Highlights from the Report
- Oncology Wins: Pfizer announced positive Phase 3 data for multiple myeloma drug ELREXFIO, strengthening its oncology pipeline.
- Regulatory Milestone: The company received its first FDA approval for a new drug (details not disclosed).
- Employee Share Offering: Pfizer filed an $8.42 billion shelf registration for employee share offerings.
Future Guidance
Pfizer maintained its full-year 2026 revenue guidance in the range of $59.5 billion to $62.5 billion, signaling management confidence in sustained growth.
Stock Impact
The article did not specify the stock's immediate reaction, but the positive results and reaffirmed guidance could bolster investor confidence.
What This Means for Investors
Pfizer's results highlight strength in oncology, a key strategic focus as COVID-19 vaccine revenues decline. Continued innovation and regulatory approvals may provide future growth drivers.
Frequently Asked Questions
Found this useful? Share it